Pharmaceuticals
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines
* The collaboration will develop an innovative genomic-based clinical treatment platform * The goal of the collaboration is to accelerate the R&D and commercialization of innovative medicines SHANGHAI, Nov. 11, 2020 /PRNewswire/ --OrigiMed, a China-based leading precision medicine company and...
2020-11-11 21:26
7350
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced new preclinical data fromin vivo and in vitro studies of...
2020-11-11 21:00
5289
Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702
SHANGHAI, Nov. 11, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company with global aspirations to discover, develop, and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today that the first patient was enrolled and a...
2020-11-11 17:08
1357
Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting
HANGZHOU and NANJING, China, Nov. 10, 2020 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focuses on developing novel cellular immunotherapy, today announced that their preliminary data including the pre-clinical development, manufacturing, and investigator initi...
2020-11-10 22:30
1707
Volition Veterinary Presents Expert Report Ahead of First Product Launch
* A Look to the Future of Cancer Diagnostics compiles insight from four veterinary cancer experts * Report provides insight into the clinical impact of early cancer detection, and recent advances * Experts also reviewed data on the Nu.Q™ Vet Cancer Screening Test, providing opinion and guid...
2020-11-10 21:00
6345
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced initial results from its U.S. phase 1 clinical trial (NCT...
2020-11-09 21:12
3951
GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit
PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ -- GenScript USA Inc., the world's
leading research reagent provider, announced today that the U.S. Food and Drug
Administration (FDA) has grantedEmergency Use Authorization (EUA)
2020-11-09 20:30
3908
TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)
TAIPEI, Nov. 9, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercial...
2020-11-09 18:22
1846
Inmagene Biopharmaceuticals closed $21 million Series B financing, making the total raised to date over $40 million
SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today that it had closed a$21 million Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital, SCVC and a few other investors. The Series B financing will b...
2020-11-09 08:00
2236
CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients
TAIPEI and SAN DIEGO, Nov. 6, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced its clinical partner- Center for Advanced Research an...
2020-11-06 22:00
3553
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study
SEOUL, South Korea, Nov. 6, 2020 /PRNewswire/ -- On October 27, the bridging study results on Fexuprazan, developed by the Korean pharmaceutical company, Daewoong Pharmaceutical (Daewoong; CEOSengho Jeon), was published in the SCI medical journal Alimentary Pharmacology and Therapeutics (AP&T). F...
2020-11-06 22:00
2683
New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
Key Highlights: * Specialised Therapeutics Asia (STA) to make QINLOCK® (ripretinib) available to appropriate patients inAustralia, New Zealand, Singapore, Malaysia and Brunei following exclusive distribution agreement * QINLOCK is already approved by the Therapeutics Good Administration (TGA)...
2020-11-06 05:30
4308
Porton Biologics Launched Gene and Cell Therapy CDMO Platform to Rank Among the Top of Pharma Solutions Platforms
SUZHOU, China, Nov. 5, 2020 /PRNewswire/ -- On November 1, the Opening Ceremony of Porton Biologics Gene and Cell Therapy CDMO Platform was held in Suzhou,China . As Porton Biologics is committed to building an end-to-end gene and cell therapy CDMO service platform, the phase I construction of th...
2020-11-05 15:35
5402
Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)
SHANGHAI, Nov. 5, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, recently announced that the Center for Drug Evaluation (CDE) ...
2020-11-05 13:59
1410
Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19
TAIPEI and SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc.
(TPEx: 6492), a clinical-stage biopharmaceutical company focused on
next-generation DNA Damage Response (DDR) therapeutics for the treatment of
cancer, today announced that it has submitted an Investigational New Drug
2020-11-02 22:00
1766
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors
MELBOURNE, Australia, Oct. 30, 2020 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of highly experienced ophthalmic industry expert,Tracy Valorie, as a new member to the company's Board of Directors. Ms Valorie is rec...
2020-10-30 20:00
1903
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide
SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon, KRX: 069620) announced on October 26 that the collaborative clinical research agreement between Daewoong and Tufts Medical Center was signed to prepare for the phase 2 clinical study of DWRX2003 (active i...
2020-10-29 21:00
2276
Yuyu Pharma Announces the Introduction of Anti-Bribery Management System to meet Global Standards
SEOUL, South Korea, Oct. 28, 2020 /PRNewswire/ -- On October 28, 2020, Yuyu Pharm (CEO Robert Wonsang Yu, KRX 000220) initiated steps to incorporate ISO 37001 Anti-bribery management system to strengthen the company's compliance system. During the introduction ceremony of ISO 37001 held at Yuyu P...
2020-10-28 21:00
1821
I-Mab Announces Upcoming Participation at November Conferences
SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences i...
2020-10-28 20:00
2750
Yiling Pharmaceutical: Revenue and Net Profit Attributable to the Parent Company for the First Three Quarters Already Exceeded the Full Year 2019
SHIJIAZHUANG, China, Oct. 28, 2020 /PRNewswire/ -- On October 27, Yiling Pharmaceutical (002603.SZ) released its 2020 third quarter report. In the first three quarters of the year, Yiling Pharmaceutical achieved the total operating revenue of6.447 billion yuan (about US$962 million), a 48.31% yea...
2020-10-28 17:04
6634
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 321 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 293 media titles]
2025-01-13 10:44
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
LANDI Global Unveils Flagship Cx20: Elevating business efficiency and customer experience with a next-generation Windows-powered terminal
[Picked up by 274 media titles]
2025-01-11 22:30
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20153
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6464
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5488
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4903
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4875
